The daily chart on VKTX recently did a golden cross (50 day EMA crossed above 200 day EMA), then pulled back to find support on the 200 day EMA. The company has a strong drug development pipeline and is a potential takeover target of a larger pharma company. 15 analysts currently gave an average 12-month price target of $92 for VKTX. The recent pullback is a great opportunity to get into this stock before it takes off!
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.